255 related articles for article (PubMed ID: 23893090)
1. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.
Lüke J; Nassar K; Lüke M; Grisanti S
Graefes Arch Clin Exp Ophthalmol; 2013 Oct; 251(10):2403-13. PubMed ID: 23893090
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab as adjuvant for neovascular glaucoma.
Beutel J; Peters S; Lüke M; Aisenbrey S; Szurman P; Spitzer MS; Yoeruek E; ; Grisanti S
Acta Ophthalmol; 2010 Feb; 88(1):103-9. PubMed ID: 18811641
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up.
Arcieri ES; Paula JS; Jorge R; Barella KA; Arcieri RS; Secches DJ; Costa VP
Acta Ophthalmol; 2015 Feb; 93(1):e1-6. PubMed ID: 24989855
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series.
Kotecha A; Spratt A; Ogunbowale L; dell'Omo R; Kulkarni A; Bunce C; Franks WA
Arch Ophthalmol; 2011 Feb; 129(2):145-50. PubMed ID: 21320957
[TBL] [Abstract][Full Text] [Related]
6. Intracameral ranibizumab and subsequent mitomycin C augmented trabeculectomy in neovascular glaucoma.
Elmekawey H; Khafagy A
J Glaucoma; 2014 Sep; 23(7):437-40. PubMed ID: 23632398
[TBL] [Abstract][Full Text] [Related]
7. Intracameral bevacizumab for iris rubeosis.
Grisanti S; Biester S; Peters S; Tatar O; Ziemssen F; Bartz-Schmidt KU;
Am J Ophthalmol; 2006 Jul; 142(1):158-60. PubMed ID: 16815268
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.
Yazdani S; Hendi K; Pakravan M; Mahdavi M; Yaseri M
J Glaucoma; 2009; 18(8):632-7. PubMed ID: 19826393
[TBL] [Abstract][Full Text] [Related]
9. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation.
Shin JP; Lee JW; Sohn BJ; Kim HK; Kim SY
J Glaucoma; 2009; 18(8):589-94. PubMed ID: 19826387
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma.
Hasanreisoglu M; Weinberger D; Mimouni K; Luski M; Bourla D; Kramer M; Robinson A; Axer-Siegel R
Eur J Ophthalmol; 2009; 19(4):607-12. PubMed ID: 19551676
[TBL] [Abstract][Full Text] [Related]
11. [Anti-VEGF therapy in the treatment of anterior segment neovascularization secondary to central retinal vein occlusion].
Kabesha TB; Glacet-Bernard A; Rostaqui O; Souied EH
J Fr Ophtalmol; 2015 May; 38(5):414-20. PubMed ID: 25956562
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab.
Lupinacci AP; Calzada JI; Rafieetery M; Charles S; Netland PA
Adv Ther; 2009 Feb; 26(2):208-16. PubMed ID: 19234680
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor for neovascular glaucoma.
Simha A; Aziz K; Braganza A; Abraham L; Samuel P; Lindsley KB
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD007920. PubMed ID: 32027392
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
[TBL] [Abstract][Full Text] [Related]
15. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection.
Ishibashi S; Tawara A; Sohma R; Kubota T; Toh N
Arch Ophthalmol; 2010 Dec; 128(12):1539-45. PubMed ID: 21149776
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study.
Sasamoto Y; Oshima Y; Miki A; Wakabayashi T; Song D; Matsushita K; Hamasaki T; Nishida K
J Ocul Pharmacol Ther; 2012 Feb; 28(1):41-8. PubMed ID: 21992534
[TBL] [Abstract][Full Text] [Related]
17. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients.
Duch S; Buchacra O; Milla E; Andreu D; Tellez J
J Glaucoma; 2009 Feb; 18(2):140-3. PubMed ID: 19225351
[TBL] [Abstract][Full Text] [Related]
18. Regression of rubeosis in the fellow eye after intravitreal ranibizumab injection.
Lüke J; Nassar K; Grisanti S; Lüke M
Graefes Arch Clin Exp Ophthalmol; 2013 Jan; 251(1):371-3. PubMed ID: 23132337
[No Abstract] [Full Text] [Related]
19. Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.
Tatsumi T; Yamamoto S; Uehara J; Sugawara T; Baba T; Inoue M; Hata H; Mitamura Y
Graefes Arch Clin Exp Ophthalmol; 2013 May; 251(5):1355-60. PubMed ID: 23250484
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab Plus Combined Surgery for Treatment of Neovascular Glaucoma with Vitreous Hemorrhage.
Li XJ; Yang XP; Li QM; Wang YY; Lyu XB
Chin Med J (Engl); 2015 Aug; 128(15):2078-83. PubMed ID: 26228222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
